Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

ClinicalTrials.gov ID: NCT02684578

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02684578. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

Study identification

NCT ID
NCT02684578
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
66 participants

Conditions and interventions

Eligibility (public fields only)

Age range
55 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2016 (Type not available)
Primary completion
Apr 2022 (Actual)
Completion
Oct 2022 (Actual)
Last update posted
Jun 9, 2023

2016 – 2022

United States locations

U.S. sites
12
U.S. states
5
U.S. cities
10
Facility City State ZIP Site status
University of California, Davis Davis California 95616 —
Palo Alto Veteran Affairs Medical Center Palo Alto California 94304 —
Retinal Consultants Medical Group Sacramento California 95819 —
San Francisco Veteran Affairs Medical Center San Francisco California 94121 —
University of California San Francisco San Francisco California 94143 —
California Retina Consultants Santa Maria California 93454 —
North Bay Vitreoretinal Consultants Santa Rosa California 95403 —
Retina Health Center Fort Myers Florida 33907 —
Northwestern University Chicago Illinois 60611 —
University of Illinois at Chicago Chicago Illinois 60612 —
Oregon Health and Science University Portland Oregon 97239 —
Austin Retina Associates Austin Texas 78705 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02684578, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2023 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.